Evaluation of Efficacy of Cilostazol on Type 2 Diabetes with Ischemic Disease of Lower Extremity by Transcutaneous Oxygen Pressure Measurement

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-09000441

Enrollment

Unknown

Registered

2009-06-24

Start date

2007-02-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus combined with ischemic disease of lower extremity

Interventions

Group B:aspirin 100mg, orally taken once daily for 8 weeks

Eligibility

Sex/Gender

All

Age

35 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed as T2DM; 2. Male and female aged 35 to 80 years old; 3. Ischemic symptoms at lower extremity; 4. The supine TcPO2<40mmHg.

Exclusion criteria

Exclusion criteria: 1. Taking anti-platelet and anticoagulant drugs in 2 weeks before the trial; 2. Lower extremity edema; 3. Hemodynamic instability; 4. Hemorrhagic disease or hemorrhagic tendency; 5. Pregnant or lactating woman; 6. Heart failure or liver failure; 7. Received a surgery in a month before the trial; 8. Be allergy to aspirin or cilostazol.

Design outcomes

Primary

Measure	Time frame
supine TcPO2;Improvement of ischemic symptom of low extremity;	—

Countries

China

Contacts

Public ContactLi Yan

hfxyl@163.net+86 13719165213

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026